Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Public ClinicalTrials.gov record NCT02184195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Study identification
- NCT ID
- NCT02184195
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Interventions
- Olaparib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2014
- Primary completion
- Jan 14, 2019
- Completion
- Jan 26, 2023
- Last update posted
- Sep 12, 2023
2014 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | 85234 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Stanford | California | 94305-5720 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Boca Raton | Florida | 33486 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Commack | New York | 11725 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10022 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02184195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 12, 2023 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02184195 live on ClinicalTrials.gov.